{"id":175931,"date":"2026-01-22T13:44:12","date_gmt":"2026-01-22T18:44:12","guid":{"rendered":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-ltd-smspharma-q2-2025-earnings-call-transcript\/"},"modified":"2026-01-22T13:44:12","modified_gmt":"2026-01-22T18:44:12","slug":"sms-pharmaceuticals-ltd-smspharma-q2-2025-earnings-call-transcript","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-ltd-smspharma-q2-2025-earnings-call-transcript\/","title":{"rendered":"SMS Pharmaceuticals Ltd (SMSPHARMA) Q2 2025 Earnings Call Transcript"},"content":{"rendered":"

SMS Pharmaceuticals Ltd (NSE: SMSPHARMA) Q2 2025 Earnings Call dated Nov. 13, 2024<\/span><\/strong><\/p>\n

Corporate Participants:<\/h2>\n

Vamsi Krishna Potluri<\/strong> \u2014 Executive Director<\/em><\/p>\n

Analysts:<\/h2>\n

R.V.G. Krishna<\/strong> \u2014 Analyst<\/em><\/p>\n

Deep Gandhi<\/strong> \u2014 Analyst<\/em><\/p>\n

Shaurya Punyani<\/strong> \u2014 Analyst<\/em><\/p>\n

Presentation:<\/h2>\n

Operator<\/strong><\/p>\n

Ladies and gentlemen, good day, and welcome to SMS Pharmaceuticals Limited Q2 FY ’25 Earnings Conference Call. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. [Operator Instructions]<\/p>\n

Today we have with us, Mr. Vamsi Krishna Potluri, Executive Director; Mr. Lakshmi Narayana Tammineedi, Chief Financial Officer; and Mr. Thirumalesh Tumma, Company Secretary & Compliance Officer.<\/p>\n

I now hand the conference over to Mr. Vamsi Krishna Potluri, Executive Director. Thank you. And over to you, sir.<\/p>\n

Vamsi Krishna Potluri<\/strong> \u2014 Executive Director<\/em><\/p>\n

Good afternoon, and a warm welcome to you all for joining us Q2 FY ’25 earnings call. I hope everyone has had an opportunity to go through our financial results and investor presentation, which have been uploaded to the stock exchange and our company website.<\/p>\n

I’m pleased to report that solid and sustained demand for our products reflect our success in capitalizing on growing market opportunities. Our strategy of a diversified API portfolio is delivering favorable outcomes with the benefits to our investors. We are expanding our market presence and reinforcing our position as a trusted partner for complex and profitable APIs.<\/p>\n

Now coming over to our financial performance…<\/p>\n

Operator<\/strong><\/p>\n

Sir, sorry to interrupt you before you go ahead. Sir, your audio is not coming little clear. Can you come little closer to the mic, please?<\/p>\n

Vamsi Krishna Potluri<\/strong> \u2014 Executive Director<\/em><\/p>\n

Sure. So now coming over to our financial performance in Q1 FY ’25 and H1 FY ’25. In Q2 FY ’25, I am pleased to report an 18% year-on-year increase in revenues from operations, reaching INR196.75 crores. This growth was driven by healthy volume growth across our portfolio. Sequentially, revenue from operations was higher by 20%. For the first half of FY ’25, revenue from operations reached INR361.2 crores, reflecting a 20% year-on-year growth, led by a strategic focus on expanding volumes in key APIs.<\/p>\n

In terms of margins, our Q2 gross margin stood at 30%, showing some decline yearly and sequentially, primarily impacted by rising raw material costs due to geopolitical tensions. For the half year, gross margins were stable at 32%. Additionally, we faced pricing pressure amid broader industry challenges. Though we are optimistic about stabilization in the near future, despite these headwinds, our EBITDA margins held steady at 16% for Q2 and 18% in the first half of FY ’25, thanks to our ongoing focus on operational efficiency.<\/p>\n

Our PAT rose to INR14.1 crores in Q2, up 20% year-on-year with PAT margins remaining consistent at 7%. For the first half of FY ’25, PAT reached INR30.58 crores, making a robust 45% year-on-year growth, primarily driven by better performance and lower financial costs. This improved PAT margins to 8.5% for H1 FY ’25 compared to 7% for H1 FY ’24.<\/p>\n

Now coming to our segmental highlights. Our revenue growth was led by robust growth in ARVs and anti-inflammatory segment. I am pleased to report that ARV has rebounded strongly, which aligns with what we communicated earlier. Ibuprofen sales have continued on a solid growth trajectory supported by an expanding customer base, deeper engagement with existing clients and optimized production process. We maintained our leadership position in the anti-diabetic segment. Our other therapeutic categories continue to do well and are characterized by our consistent influx of new customers.<\/p>\n

On the operational front, I am proud to report that we have received the EDQM certificate for our Vizag facility to supply ibuprofen for Europe. This reflects our commitment to quality and compliance with global standards and pursuing market leadership in our select API globally. Our backward integration and capacity expansion projects to support long-term growth is progressing as planned. We are on track to achieve commercialization by Q4 FY ’25. We anticipate sustained growth in our key API supported by an expanding customer base for the rest of the year. This positions us for a strong performance in the second half of the financial year, keeping us on track to achieve our outlook for FY ’25.<\/p>\n

Thank you. We are ready to answer any questions.<\/p>\n

Questions and Answers:<\/h2>\n

Operator<\/strong><\/p>\n

Thank you very much. [Operator Instructions] The first question is from the line of R.V.G. Krishna from Sri Venkateswara Enterprises. Please go ahead.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

Good afternoon, all. Thank you for the quick summary and the update for the quarterly and financial results. Sir, I just wanted to know what would be the growth drivers for the company in terms of increasing the profit along with the INR150 crores capex plan which you have mentioned and what would be its role in increasing the revenues?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Yeah. Thank you for your question. So with respect to the capex, as briefed, I think the capex expansion plan will be completed by Q4 this year. The capex plan, which we have taken up, is for the backward integration of key materials for some of our critical products. Definitely, this is definitely going to add more value at the bottom-line level by pushing our margins a little bit in order to combat the price pressures, some of these products where we become more vertically integrated. So these sort of give us some respite in terms of the pricing pressure and these will make sure that we are keeping our margins intact.<\/p>\n

Operator<\/strong><\/p>\n

Mr. Krishna, do you have any follow-up question?<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] Next question is from the line of Deep Gandhi from ithought PMS. Please go ahead.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Yeah. Good afternoon, sir. Sir, I had a question related to one of our products, which is Ranolazine. Sir, if you can talk…<\/p>\n

Operator<\/strong><\/p>\n

Sorry to interrupt you. Can you please through the handset? Your voice is echoing.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Is this better now?<\/p>\n

Operator<\/strong><\/p>\n

Slightly.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure. Sir, I was talking about one of our specific products, which is Ranolazine. Sir, can you please talk about what is the global market share of this product in terms of volume and value? And what is our market share in this product if you can talk about that?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Is it Ranolazine? What is the product again.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Yes, sir. That is correct.<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Okay. So this is part of our JV product. So with respect to market share, we have around 40% market share globally. And we have a good presence with some of the key manufacturers out of India who are manufacturing this for the generic market in the U.S. And obviously, two, three critical — critically big customers in Europe. So this is part of our JV project with our partner Chemo.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure, sir. And what would be the volume market share of this product, if you can also — the total volume size of this product globally?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

So this is like, for us — for us, it’s like a 60 metric ton product. Obviously, it varies here or there. And I think in terms of volume, we’ll be at 30%, 35% in terms of global volume.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure. And sir, how has this product’s market grown over the last three to five years?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

It’s sort of consolidated, to be honest with you. It is sort of consolidated and actually it’s not growing as we anticipated. It’s sort of consolidated, too many players in the market, the prices are more or less coming down, there’s a lot of price pressure on this particular product and volumes also have not increased significantly. I think maybe if I’m not wrong, it’s flat or even there is a slight decline also in terms of volumes.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure. And sir, who would be our top competitors for this product out of India, some of the top competitors?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

I probably would not like to answer that question because we are probably talking about this company. So I would not like to name the competitors in the call. If there is anything, you can probably write to us and we will definitely respond to you.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure. Just one last question. You mentioned that the volumes have been flat. What about the pricing? How has been the pricing in the last three to five years for this product?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Again, as I told you, there has been a lot of price pressure. So definitely, there is a pricing erosion of around 10% year-on-year on this product approximately.<\/p>\n

Deep Gandhi<\/strong><\/p>\n

Sure, sir. Thank you. That answers my question.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] Next follow-up question is from the line of R.V.G. Krishna from Sri Venkateswara Enterprises. Please go ahead.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

Sir, as you have mentioned that you’re about to expand your new product line. May I know the current status? Because in the last investor concall you mentioned you were about to launch — in process of launching some 15 new products.<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

So this major capex expansion that we are doing is for our existing products. Some of the key starting materials we are actually planning to manufacture in-house. So apart from this, we have segmented around 25% of our capex for new products. So new products are still in the pipeline phase right now. They’re still not in the pipeline, few on the validation phase. So they’re not fully commercial yet. And these products will not be commercialized now because they have some patents associated with them. So I think it will take two, three years for them to commercialize.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

Understood. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] Next question is from the line of Shaurya from Arjav Partners. Please go ahead.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

Hi. Am I audible?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Yeah, go ahead.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

Sir, I wanted to know what would be your capacities post capex in Hyderabad and Vizag?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

So Hyderabad remains same because we are not doing any capex there because it is a small size. Our volume for Vizag site will be reaching around 3,000 KL.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

Okay. Volume?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Yeah, volume.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

And what is the current utilization level?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

So right now, the utilization level is at around 60%. I think maybe by [Technical Issue] we are anticipating it to go up to 75%.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

By when?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

By FY ’26.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

By FY ’26. Okay. And do we have any growth — what are the growth plans for ’26, like top-line and margins?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

So again, as we already indicated in the last call, I think we are anticipating around 15% to 20% growth on the top-line and bottom-line around 12% to 15%.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

12% to 15%?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Yeah.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

And margins will remain around 20%?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Margins will be around 18%. Right now, we are already at 18%. I think it will be in that same range, 18% to 20%, depends on product mix and volume because we are increasing the volumes on high volume products. So I think it’s sort of will remain in that range, 18% to 20%.<\/p>\n

Shaurya Punyani<\/strong><\/p>\n

Okay, sir. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions] Next follow-up question is from the line of R.V.G. Krishna from Sri Venkateswara Enterprises. Please go ahead.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

Yeah. Sir, just wanted to check on the update of the backward integration of certain raw materials which you’re trying to do?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

As indicated in my opening speech, I think by Q4, we will be completing the capex for the vertical integration projects. So I think we will be commercial, fully backward integrated by the end of Q4.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

So are we positive will be impact on the reducing of your production? Will that increase your margins?<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

See margins, there’s a significant factor. Apart from that, dependency on like another country or different manufacturers will reduce significantly especially for some of our key products. So in the current geopolitical situation, we don’t know what will happen and how it will impact. Getting it manufactured at our own site will give us that leverage and confidence to your customers also that they will not have any supply issues. So that was our main target for initiating this vertical integration. But obviously, definitely, there will be saving on the cost as well. The profitability will definitely increase by around close to around 5% to 8% to what we currently have.<\/p>\n

R.V.G. Krishna<\/strong><\/p>\n

That’s it. Thank you, sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you very much. Ladies and gentlemen, that was the last question. I’ll now hand the conference over to Mr. Vamsi Krishna Potluri for closing comments.<\/p>\n

Vamsi Krishna Potluri<\/strong><\/p>\n

Thank you everyone for joining on this call. We are committed to delivering exceptional value to our customers, driving innovation and achieving sustainable success. Our strategic approach ensures positive outcomes for our stakeholders in upholding our dedication to sustainability. Please reach out to our IR consultant or us directly should you have any further questions. Thank you again for your time today.<\/p>\n

Operator<\/strong><\/p>\n

[Operator Closing Remarks]<\/p>\n","protected":false},"excerpt":{"rendered":"

SMS Pharmaceuticals Ltd (NSE: SMSPHARMA) Q2 2025 Earnings Call dated Nov. 13, 2024 Corporate Participants: Vamsi Krishna Potluri \u2014 Executive Director Analysts: R.V.G. Krishna \u2014 Analyst Deep Gandhi \u2014 Analyst Shaurya Punyani \u2014 Analyst Presentation: Operator Ladies and gentlemen, good day, and welcome to SMS Pharmaceuticals Limited Q2 FY ’25 Earnings Conference Call. This conference […]<\/p>\n","protected":false},"author":2377,"featured_media":147581,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6349],"tags":[10169,9175,9104,9092,14492,13743,10089],"class_list":["post-175931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-transcripts","tag-earnings","tag-earnings-call","tag-earnings-conference","tag-earnings-transcripts","tag-financial-results","tag-health-care","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":130651,"url":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":175931,"position":0},"title":"SMS Pharmaceuticals Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 15, 2022","format":false,"excerpt":"Key highlights from SMS Pharmaceuticals Ltd (SMSPHARMA) Q4 FY22 Earnings Concall Management Update: SMSPHARMA said its near-term focus remains on scaling up production for ibuprofen along with expanding the customer base for ibuprofen. Q&A Highlights: Akash Mehta of Capaz Investments asked about revenue contribution declining sharply from the ARV segment\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133740,"url":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":175931,"position":1},"title":"SMS Pharmaceuticals Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"September 7, 2022","format":false,"excerpt":"https:\/\/youtu.be\/G2_d7tTye3s Key highlights from SMS Pharmaceuticals Limited (SMSPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: Atul Kothari from Progwell Securities asked about the products under pipeline with Chemo JV. Vamsi Krishna ED replied that the products already on the pipeline are almost developed. There are 8 products as part of JV\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":41715,"url":"https:\/\/alphastreet.com\/india\/wipro-limited-wit-q2-2020-earnings-snapshot\/","url_meta":{"origin":175931,"position":2},"title":"Wipro Limited (WIT): Q2 2020 Earnings Snapshot","author":"Toby","date":"October 15, 2019","format":false,"excerpt":"-- Wipro Limited (NYSE: WIT) reported second-quarter 2020 earnings of $0.06 per share, in line with Wall Street projection -- Revenues grew 4% to $2.14 billion, vs. $2.13 billion expected. -- In Q2, IT Services revenue grew 2.5% to $2.05 billion. -- Wipro expects IT Services revenue to be $2.065\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"Earnings Update by AlphaStreet","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":175929,"url":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-ltd-smspharma-q4-2025-earnings-call-transcript\/","url_meta":{"origin":175931,"position":3},"title":"SMS Pharmaceuticals Ltd (SMSPHARMA) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"SMS Pharmaceuticals Ltd (NSE: SMSPHARMA) Q4 2025 Earnings Call dated Jun. 02, 2025 Corporate Participants: Unidentified Speaker P. Vamsi Krishna \u2014 Executed Director Lakshmi Naryana Tammineedi \u2014 Chief Financial Officer Analysts: Unidentified Participant Pranav Gandhi \u2014 Analyst Surabhi Sutaria \u2014 Analyst Anmol Ganjoo \u2014 Analyst Srihari Chintalapudy \u2014 Analyst Presentation:\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136188,"url":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-limited-smspharma-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":175931,"position":4},"title":"SMS Pharmaceuticals Limited (SMSPHARMA) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"August 18, 2022","format":false,"excerpt":"SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Q2 FY23 Earnings Concall Aug. 18, 2022 Corporate Participants: P. Vamsi Krishna -- Executed Director LakshminarayanaTammineedi -- Chief Financial Officer Analysts: Atul Kothari -- Progwell Securities -- Analyst P.D. Gupta -- Investors Forum -- Analyst Priyanka Shah -- KP Advisors -- Analyst Ankush Mahajan -- Axis\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142315,"url":"https:\/\/alphastreet.com\/india\/sms-pharmaceuticals-ltd-smspharma-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":175931,"position":5},"title":"SMS Pharmaceuticals Ltd (SMSPHARMA) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 21, 2023","format":false,"excerpt":"SMS Pharmaceuticals Ltd (NSE:SMSPHARMA) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Vamsi Krishna Potluri\u00a0--\u00a0Executive Director Unidentified Speaker\u00a0-- Analysts: Viraj Shah\u00a0--\u00a0Shah Investments -- Analyst Aditi Sawant\u00a0--\u00a0ADM Advisors -- Analyst Dipti Kothari\u00a0--\u00a0Kothari Securities -- Analyst Mahesh Vyas\u00a0--\u00a0UTI Mutual Fund -- Analyst Unidentified Participant\u00a0--\u00a0-- Analyst Parth Vasani\u00a0--\u00a0KK Advisors -- Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/175931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2377"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=175931"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/175931\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/147581"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=175931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=175931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=175931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}